Akebia Therapeutics announced that a post-hoc analysis of its Phase 3 INNO2VATE trial showed vadadustat significantly reduced the combined risk of death and hospitalization compared to darbepoetin alfa in patients with anemia due to chronic kidney disease (CKD) on dialysis. Published in the Journal of the American Society of Nephrology, this analysis supports vadadustat's clinical benefits and potential as a standard treatment for dialysis-dependent CKD anemia. Vadadustat (Vafseo®) is already approved in the U.S. for this use, and the company aims to increase its adoption among healthcare providers.
Funnel has introduced Digital Measurement, a new marketing mix modeling (MMM) software that integrates MMM, Multi-Touch Attribution (MTA), and ad platform signals into one calibrated system. This approach addresses the limitations of relying on a sin...
Zealand Pharma held an Extraordinary General Meeting on May 26, 2026, where all proposals were approved, including the election of Camilla Sylvest to the Board of Directors. The board now consists of seven shareholder-elected members and four employe...
Nvidia has been a top AI investment as demand for AI chips surged, but the next wave of IPOs from major AI customers like SpaceX, OpenAI, and Anthropic could shift investor focus. These companies, while not competitors in hardware, may compete for in...
Salazar Resources announced a new copper-gold porphyry system discovery at its 100%-owned Monja Project in southern Ecuador, featuring high-grade surface samples. This discovery comes as global copper prices hit record highs due to supply deficits, i...
Novee has introduced Agentic Fix, an enhancement to its AI penetration testing platform that automates the transition from identifying security vulnerabilities to deploying fixes. This tool generates detailed remediation guidance based on validated e...
